🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Different Volumes of SPSIP Block in Breast Surgery

RecruitingNAAges 18 Years - 75 YearsFemaleBursa City Hospital
NCT07783386 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized, double-blind study will compare the effectiveness of three different volumes of serratus posterior superior intercostal plane block for postoperative pain control in patients undergoing unilateral breast surgery with axillary lymph node dissection. Ninety participants will be randomly assigned to receive 20 mL, 30 mL, or 40 mL of 0.25% bupivacaine. The primary outcome is total tramadol consumption during the first 24 hours after surgery. Pain scores, time to first analgesic request, rescue analgesic use, quality of recovery, postoperative nausea and vomiting, block success, and block-related complications will also be evaluated.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 18 to 75 years * American Society of Anesthesiologists physical status I-III * Scheduled for elective unilateral breast surgery under general anesthesia * Able to provide written informed consent Exclusion Criteria: * Refusal to participate * Coagulopathy * Known allergy to local anesthetics or a history of local anesthetic systemic toxicity * Liver or kidney failure * Uncontrolled diabetes mellitus * Uncontrolled hypertension * Cognitive impairment or inability to understand the study procedures * Chronic pain requiring opioid therapy * Current antidepressant use * Neuropathic pain * Infection at the block injection site * Pregnancy, suspected pregnancy, or breastfeeding * Clinically significant frailty
💊

What it tests

  • Bupivacaine 0.25% (20 mL)
  • Bupivacaine 0.25% (30 mL)
  • Bupivacaine 0.25% (40 mL)
📍

Where

1 site
Bursa City Hospital
Nilufer, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy